Imiquimod Accelerated Antitumor Response by Targeting Lysosome Adaptation in Skin Cancer Cells

Shu-Hao Chang,Chun-Ying Wu,Kai-Cheng Chuang,Shi-Wei Huang,Zheng-Yi Li,Sin-Ting Wang,Zi-Lun Lai,Cheng-Chung Chang,Yi-Ju Chen,Tak-Wah Wong,Jun-Kai Kao,Jeng-Jer Shieh

DOI: https://doi.org/10.1016/j.jid.2021.01.034

IF: 7.59

2021-09-01

Journal of Investigative Dermatology

Abstract:Lysosomal adaptation is a cellular physiological process in which the number and function of lysosomes are regulated at the transcriptional and posttranscriptional levels in response to extracellular/intracellular cues or lysosomal damage. Imiquimod, a synthetic Toll-like receptor 7 ligand with hydrophobic and weak basic properties, exhibits both antitumor and antiviral activity against various skin malignancies as a clinical treatment. Interestingly, imiquimod has been suggested to be highly concentrated in the lysosomes of plasmacytoid DCs, indicating that imiquimod could modulate lysosome function after sequestration in the lysosome. Here, we found that imiquimod not only induced lysosomal membrane permeabilization and dysfunction but also increased lysosome biogenesis to achieve lysosomal adaptation in cancer cells. Imiquimod-induced ROS production but not lysosomal sequestration of imiquimod was the major cause of lysosomal adaptation. Moreover, imiquimod-induced lysosomal adaptation occurred through lysosomal Ca release and activation of the calcineurin/TFEB axis to promote lysosome biogenesis. Finally, depletion of TFEB sensitized skin cancer cells to imiquimod-induced apoptosis in vitro and in vivo. In summary, disruption of lysosomal adaptation might represent a therapeutic strategy for synergistically enhancing the cytotoxicity of imiquimod in skin cancer cells.

dermatology